Liraglutide vs Semaglutide: The GLP-1 Drug That Came Before Ozempic
Liraglutide came before semaglutide. When Victoza was approved for T2D in 2010 and Saxenda for obesity in 2014, they were the state-of-the-art GLP-1 drugs. They are still approved and prescribed in 2026 — but the clinical landscape has shifted substantially since semaglutide and tirzepatide arrived.
Understanding how liraglutide relates to semaglutide tells you something about how GLP-1 drug development works and why the newer drugs are more effective.
The structural relationship
Liraglutide and semaglutide are both GLP-1 receptor agonist peptides made by Novo Nordisk. Semaglutide was developed as an improved version of liraglutide.
The key structural modification: Novo Nordisk added a fatty-acid side chain to semaglutide that binds more strongly to albumin (the main blood protein). This albumin binding protects semaglutide from degradation and slows its elimination from the body.
Result:
- Liraglutide half-life: approximately 13 hours → requires daily injection
- Semaglutide half-life: approximately 168 hours (7 days) → once-weekly injection
Beyond dosing frequency, the sustained higher plasma concentration with once-weekly semaglutide produces stronger receptor activation over the week — which translates to greater appetite suppression and more weight loss at equivalent or comparable doses.
Clinical comparison
| Liraglutide (Saxenda/Victoza) | Semaglutide (Wegovy/Ozempic) | |
|---|---|---|
| Half-life | ~13 hours | ~168 hours |
| Injection frequency | Daily | Weekly |
| Max obesity dose | 3 mg (Saxenda) | 2.4 mg (Wegovy) |
| Weight loss (obesity trials) | ~8–9% | ~15–17% |
| A1C reduction (T2D) | ~1.0–1.8% (Victoza) | ~1.3–2.0% (Ozempic) |
| CV outcome trial | LEADER: −13% MACE (T2D, established CVD) | SUSTAIN-6: −26% MACE; SELECT: −20% (established CVD, no T2D req) |
| Approved since | 2010 (T2D), 2014 (obesity) | 2017 (T2D), 2021 (obesity) |
STEP 8: the direct head-to-head
STEP 8 (published NEJM 2022) randomised 338 adults with obesity to semaglutide 2.4 mg vs liraglutide 3 mg for 68 weeks. The result was definitive:
| Drug | Mean weight loss | ≥10% weight loss | ≥15% weight loss |
|---|---|---|---|
| Semaglutide 2.4 mg | −15.8% | 70% | 55.6% |
| Liraglutide 3 mg | −6.4% | 27.6% | 17.1% |
This is not a close comparison. Semaglutide produced more than twice the weight loss of liraglutide in the same population under the same conditions.
Where liraglutide still has a role
Insurance coverage lag: Saxenda has been on commercial formularies since 2014 — before Wegovy existed. Some plans that have not yet added Wegovy for obesity still cover Saxenda. A patient whose only covered option is Saxenda gets more weight-loss benefit from Saxenda than from no GLP-1 at all. Saxenda is sometimes used as a "bridge" while Wegovy prior authorisation is pending.
Step therapy: Some plans list Saxenda or Victoza as required steps before approving Wegovy or Ozempic. A patient who needs to document "failure on a prior GLP-1" may start on liraglutide for step therapy purposes.
T2D with LEADER-specific CV documentation: The LEADER trial tested Victoza (liraglutide 1.8 mg for T2D). For clinical purposes, semaglutide's SUSTAIN-6 and SELECT data shows stronger CV risk reduction, but prescribers familiar with liraglutide's LEADER data for specific patient types may have reasons to prefer it.
Continuation for stable patients: A patient who has been on Victoza for years, is stable and tolerating it well, has no clinical reason to switch. Changing for the sake of novelty is not a clinical rationale.
The current-generation perspective
For a new T2D or obesity patient starting GLP-1 therapy in 2026, liraglutide is not the usual first consideration. Semaglutide or tirzepatide are available, more effective, and weekly rather than daily. The choice of which generation of GLP-1 to use is primarily driven by insurance formulary decisions and the prescriber's clinical assessment — not pharmacological preference for liraglutide.
For the current-generation comparison, see Ozempic vs Mounjaro and best GLP-1 for type 2 diabetes.
Frequently asked questions
What is liraglutide?
Liraglutide is a GLP-1 receptor agonist peptide, available as Victoza (1.8 mg daily for type 2 diabetes, approved 2010) and Saxenda (3 mg daily for obesity, approved 2014). It was the first GLP-1 widely used for weight management. Novo Nordisk also makes it. Semaglutide (Ozempic, Wegovy) is a structural modification of liraglutide with longer duration of action.
How is semaglutide different from liraglutide?
Semaglutide is a structural derivative of liraglutide with modifications that increase albumin binding and extend the half-life from ~13 hours (liraglutide) to ~168 hours (semaglutide). This allows once-weekly dosing vs daily. The higher sustained receptor exposure with semaglutide also produces greater weight loss — approximately 2x in head-to-head trials.
Is liraglutide still used in 2026?
Yes. Liraglutide (Victoza, Saxenda) is still FDA-approved and prescribed. It is primarily used when: (1) a patient's insurance covers liraglutide but not semaglutide; (2) as a step-therapy requirement before semaglutide; (3) when there are clinical reasons to prefer shorter-acting liraglutide; or (4) as a historical continuation for patients already stable on it.
Does liraglutide have cardiovascular benefits?
Yes. The LEADER trial (liraglutide 1.8 mg, Victoza T2D dose) showed a 13% relative risk reduction in MACE in T2D patients with established cardiovascular disease. Saxenda (3 mg) does not have a specific approved cardiovascular indication, though the SCALE outcomes data showed some CV benefit. Semaglutide (Ozempic) showed a 26% MACE risk reduction in SUSTAIN-6 — stronger than liraglutide's LEADER result.